KFDA to strengthen monitoring of Lamisil cream
Published: 2006-07-18 06:56:00
Updated: 2006-07-18 06:56:00
The Korea Food and Drug Administration (KFDA) recently said it will strengthen monitoring of Lamisil cream marketed by Norvartis Korea in response to the occurrence of its side effect vitiligo, which was reported by a pharmacist living in Pyungtaik, Kyunggi Province.
Vitiligo is a pigmentation...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
